<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-87728</identifier>
<setSpec>0001-7310</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Etanercept and neoplasms</dc:title>
<dc:description xml:lang="en">The introduction of tumor necrosis factor (TNF) beta blockers has make it possible to obtain a significant advance in the control and knowledge of some inflammatory diseases, among them psoriasis.TNF is a cytokine that plays a key role in the control of infections and neoplasms. The increase of the risk of developing a neoplasm during the use of this group of drugs is one of the more debated adverse effects in the literature. We present the clinical case of one patient with long-course psoriasis who developed a breast adenocarcinoma after initiating treatment with etanercept. In this article, we provide a brief review on the possible associations existing between the use of anti-TNF therapy and the risk of the appearance of come neoplasms, among which leukemias, lymphomas and some solid tumors stand out (AU)</dc:description>
<dc:creator>Sánchez-Carazo, J. L</dc:creator>
<dc:creator>García-Rabasco, A</dc:creator>
<dc:creator>Esteve, A</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">La introducción de los fármacos bloqueadores del factor de necrosis tumoral (TNF) ha permitido un gran avance en el control y conocimiento de ciertas enfermedades inflamatorias, entre las que se incluye la psoriasis. El TNF es una citocina que desempeña un papel clave en el control de infecciones y neoplasias. El incremento del riesgo de desarrollar una neoplasia durante el empleo de este grupo de fármacos es uno de los efectos adversos más discutidos en la literatura. Presentamos el caso clínico de una paciente con psoriasis de larga evolución que desarrolló un adenocarcinoma de mama tras iniciar el tratamiento con etanercept. En este artículo realizamos una breve revisión acerca de la posible asociación existente entre el empleo de terapia anti-TNF y el riesgo de aparición de ciertas neoplasias, entre las que destacan las leucemias, los linfomas y determinados tumores sólidos (AU)</dc:description>
<dc:source>Actas Dermosifiliogr;101(supl.1): 88-96, mayo 2010. ilus</dc:source>
<dc:identifier>ibc-87728</dc:identifier>
<dc:title xml:lang="es">Etanercept y neoplasias</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d29622</dc:subject>
<dc:subject>^d238^s22012</dc:subject>
<dc:subject>^d238^s22053</dc:subject>
<dc:subject>^d238^s22016</dc:subject>
<dc:subject>^d29591^s22038</dc:subject>
<dc:subject>^d8398^s22016</dc:subject>
<dc:subject>^d9562^s22016</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d23872^s22016</dc:subject>
<dc:subject>^d12002^s22016</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d23872^s22012</dc:subject>
<dc:subject>^d12002^s22012</dc:subject>
<dc:subject>^d12002^s22067</dc:subject>
<dc:subject>^d29591^s22073</dc:subject>
<dc:subject>^d9562^s22053</dc:subject>
<dc:subject>^d9562^s22012</dc:subject>
<dc:subject>^d9062</dc:subject>
<dc:subject>^d8398^s22012</dc:subject>
<dc:type>article</dc:type>
<dc:date>201005</dc:date>
</metadata>
</record>
</ibecs-document>
